Highlights Galmed Pharmaceuticals Ltd.

Equities

GLMD

IL0011313900

Market Closed - Nasdaq Other stock markets 21:30:00 14/05/2024 BST			5-day change	1st Jan Change
0.4037 ^USD	+3.97%		-0.88%	-11.27%

04-04	Galmed Pharmaceuticals Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
03-15	Galmed Pharmaceuticals Ltd. Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of Nash and Liver Fibrosis	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Galmed Pharmaceuticals Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	04-04	CI
Galmed Pharmaceuticals Ltd. Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of Nash and Liver Fibrosis	03-15	CI
Galmed Pharmaceuticals Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-22	CI
Galmed Pharmaceuticals Expects Minimum Six Months Delay in Primary Sclerosing Cholangitis Study	11-20	MT
Galmed Pharmaceuticals Ltd. Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal Fibrosis	26/09/23	CI
Galmed Pharmaceuticals Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	09/08/23	CI
Galmed Pharmaceuticals Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	01/06/23	CI
Galmed Pharmaceuticals Ltd. Announces Initiation of a Clinical Development Program to Evaluate Aramchol meglumine for the Treatment of Primary Sclerosing Cholangitis	09/05/23	CI
Galmed Pharmaceuticals Forms a Strategic Partnership with OnKai	04/05/23	CI
Galmed Pharmaceuticals Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	29/03/23	CI
Galmed Pharmaceuticals Receives US Patent for Aramchol Meglumine Salt	08/02/23	MT
Galmed Pharmaceuticals Ltd. Announces Issuance of New Composition of Matter Patent for Aramchol Meglumine Salt	08/02/23	CI
Galmed Pharmaceuticals Ltd. Reports Results from the Open-Label Part of the Armor Study Showing Improvements in Histology, Imaging, and Biomarkers with Aramchol	04/01/23	CI
Galmed Pharmaceuticals Gets Extension to Regain Compliance With Nasdaq's Bid Price Requirement	15/12/22	MT
Galmed Pharmaceuticals Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	16/11/22	CI
Galmed Pharmaceuticals Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	04/08/22	CI
Galmed Pharmaceuticals Ltd. Reports Significant Anti-Fibrotic Effects of Aramchol in A Lung Fibrosis Model	07/07/22	CI
Galmed Pharmaceuticals Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	17/05/22	CI
Galmed Pharmaceuticals Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	02/05/22	CI
Galmed Pharmaceuticals Ltd. Reports Interim Results from the Open-Label Part of the Armor Study with Aramchol Showing Robust Fibrosis Improvement Across Multimodality Histological Assessment	28/04/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Galmed Pharmaceuticals Ltd.

Equities

GLMD

IL0011313900

Highlights

Filters